New combo aims to boost powerful cancer treatment
NCT ID NCT07478848
Summary
This early-stage study is testing if a combination of targeted radiation and an oral antibiotic is safe and feasible to give before a patient's own immune cells are engineered to fight their cancer (CAR-T therapy). It is for adults with aggressive B-cell lymphomas that have come back or not responded to other treatments. The goal is to see if this 'bridging' approach helps control the cancer and improves the safety and effectiveness of the subsequent CAR-T treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Abramson Cancer Center, University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.